Quest Diagnostics (DGX) EPS (Basic) (2009 - 2026)

Quest Diagnostics has disclosed EPS (Basic) across 18 years of filings, most recently posting $2.27 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $2.27, up 15.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.17 (up 14.48% YoY), and the FY2025 annual result was $8.87, up 14.01% from the prior year.
• EPS (Basic) came in at $2.27 for Q1 2026 at Quest Diagnostics, up from $2.21 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $2.97 in Q1 2022 to a low of $0.93 in Q4 2022.
• The 5-year median for EPS (Basic) is $2.01 (2024), against an average of $2.04.
• Across the five-year window, EPS (Basic) plunged 71.12% in 2022 and soared 84.95% in 2023, its largest moves.
• Quest Diagnostics' EPS (Basic) stood at $0.93 in 2022, then jumped by 84.95% to $1.72 in 2023, then increased by 15.12% to $1.98 in 2024, then advanced by 11.62% to $2.21 in 2025, then climbed by 2.71% to $2.27 in 2026.
• The last three EPS (Basic) figures came in at $2.27 (Q1 2026), $2.21 (Q4 2025), and $2.18 (Q3 2025), per Business Quant data.